Meet the team
Directors
Sue Langham, PhD
-
A Co-Founder and seasoned Market Access Specialist and Health Economist with over 30 years of experience spanning consultancy, the pharmaceutical industry, NICE, and academia. She leads Maverex’s leadership team, shaping strategic direction and defining the company’s core values—scientific excellence, integrity, ingenuity, collaboration, inclusion, and sustainability. Sue feels privileged to work alongside talented scientists who share a passion for scientific quality and professional curiosity. Throughout her career, she has supported pharmaceutical and MedTech companies as a trusted advisor, driving successful market access and reimbursement strategies for innovative health technologies that improve patient outcomes and deliver healthcare value.
Director
Nick Pooley, PhD
-
With over 15 years of expertise in strategic evidence generation, Nick is an experienced evidence synthesis scientist, specialising in systematic and targeted literature reviews and environmental impact analysis. Nick works cross- functionally and is well-versed in HTA requirements across multiple markets, and understands how these shape evidence needs at the strategic level.
Nick has led numerous indirect treatment comparisons using frequentist, Bayesian, and meta-regression methods, including analyses of single-arm trials, consistently delivering evidence that stands up to rigorous scrutiny.
As a member of the leadership team, Nick supports the alignment of business operations with the company’s strategic direction and drives continuous improvements in operational performance to ensure the consistent delivery of high-quality outcomes for our clients.
Director
Antony Wright, MSc
-
A Co-Founder and experienced Environmental and Health Economist with over 20 years of experience in market access consultancy. As part of the leadership team, he oversees operations and finance while shaping the company’s strategic direction and core values. He specialises in health economic and environmental impact modelling for pharmaceutical and MedTech companies, combining expertise in modelling, analytics, and IT to deliver robust, actionable insights. Throughout his career, Antony has led successful projects in economic modelling, environmental impact, and sustainability assessment, helping establish Maverex as a leader in environmental modelling and sustainability within the healthcare sector.
Director
James Kenworthy, MBA, MSc
-
With over 20 years in healthcare, James has built a diverse career spanning R&D, Commercial, Consulting, Market Access and Health Economics roles. He was previously Head of Global HEOR and Market Access at a multinational pharma company, leading all aspects of global market access strategy, such as economic modelling, publication strategy, strategic pricing, payer interaction, value messaging and all other associated deliverables across numerous therapy areas. He has also supported 50+ technical due diligence projects, offering strategic insights into the access potential of acquisition targets through early modelling and evidence review.
Director
Lizzie Adkins, PhD
-
Lizzie is a highly experienced value communications and market access specialist with over 15 years of experience translating clinical, humanistic, and economic evidence into clear and compelling value stories. She has extensive experience working cross-functionally and has led the development of global value propositions, messaging, and value dossiers, collaborating with global leads to ensure strategic alignment, and with affiliates across multiple markets to tailor materials to local needs.
As a member of the leadership team, Lizzie is responsible for aligning business operations with the company’s strategic direction and ensuring the delivery of projects to the highest scientific standards. She is passionate about supporting the wellbeing and growth of the Maverex team and about connecting brand, people, culture, and sustainability initiatives to drive meaningful, long-term impact.
Director
Value Communications and Health Technology Assessment
Rhiannon Teague, MSc, MRes
Value Communications and Health Technology Assessment
-
Rhiannon has over seven years of healthcare communications experience and is the Value Communications team lead. She oversees the development of evidence-based materials including value dossiers, value stories, and objection handlers, ensuring they meet diverse global market needs.
With in-depth knowledge of global reimbursement landscapes, Rhiannon specialises in designing market access strategies across the product life cycle. She helps clients shape evidence generation, stakeholder engagement and publication plans that support positive reimbursement decisions, accelerate patient access, and maximise long-term value.
Beyond client work, Rhiannon is a team leader who is committed to mentoring her team and nurturing a collaborative culture.
Rebecca Mackley, PhD
Value Communications and Health Technology Assessment
-
Rebecca has extensive experience developing evidence-based value communication materials, including global value dossiers, value messages, and value stories to inform healthcare decision-making. She has contributed to HTA and pragmatic literature reviews and supported regulatory and policy document scoping for complex disease areas. Using skills gained during a PhD in cardiovascular disease, Rebecca combines scientific expertise with strategic insight to deliver impactful, audience-focused communication materials. She is skilled in creating high-level infographics for social media and supporting stakeholder engagement through workshops and collaborative initiatives. Rebecca has presented research internationally and develops high-quality publications and conference materials that effectively convey complex evidence.
Jade Armstrong, MSc
Value Communications and Health Technology Assessment
-
Jade is experienced in the preparation of value messages, project proposals, pragmatic and systematic literature reviews for various projects in a wide range of disease areas. She is a registered nurse with clinical and research experience in a broad range of therapeutic areas and healthcare systems, with in-depth knowledge of disease and treatment processes in a real-world setting.
Becky Greaves, PhD
Value Communications and Health Technology Assessment
-
Becky leads our Health Technology Assessment (HTA) work here at Maverex and brings 8+ years experience in HTA organisations and medical consultancy. She has led HTA submissions for NICE, SMC, NCPE, DMC, NIPH, and PBAC across various disease areas, including oncology, cardiovascular, urology, and rare diseases. Becky has extensive experience in designing and conducting literature reviews and is a strong medical writer across academic, payer, and patient-facing materials. She’s a skilled project manager, experienced in coordinating cross-functional teams to deliver high-quality outputs on time.
Scott Dixon, PhD
Value Communications and Health Technology Assessment
-
Scott is experienced in producing evidence-based value communications, such as global value dossiers, landscape reviews, and value propositions. He is also proficient in producing high-quality scientific, healthcare-focused social media infographics. With an academic background in neuroscience and physiology, Scott has contributed to peer-reviewed research papers, literature reviews, and conference presentations. He is also experienced in data analysis and visualisation using tools such as MATLAB, R, and Python.
Amy Heptinstall, PhD
Value Communications and Health Technology Assessment
-
Amy is a highly skilled professional in global evidence-based value communication, specialising in the development of value dossiers, messages, and stories, and objection handlers. With expertise in HTA reviews, literature reviews, manuscript preparation, and poster development, she brings a comprehensive skill set to her work. Amy has also delivered oral and poster presentations at several international conferences, demonstrating her thought leadership. With a strong academic foundation in drug discovery and development and nine years of practical experience across both academic and industrial settings, she is well-equipped to provide impactful, data-driven insights to support healthcare decision-making.
Roisin Stout, PhD
Value Communications and Health Technology Assessment
-
With a strong foundation in dermatological sciences, Roisin brings experience in evidence-based value communications, including global value dossiers, landscaping reviews, and value propositions. Her research background spans skin aging, mitochondrial disease, and melanoma, and she has held roles across academia and industry, including two years as a postdoctoral researcher developing a prognostic marker for melanoma. Roisin also completed the Innovation to Commercialisation of University Research (ICURe) programme, where she gained expertise in value proposition development, market exploration, and public engagement.
Ciara Wright, MSc
Value Communications and Health Technology Assessment
-
Ciara brings 20+ years of health economics and outcomes research expertise, spanning the pharmaceutical industry, NHS, and consultancy. Her clinical foundation as a nurse and midwife, combined with an MSc in Economic Evaluation in Healthcare, provide a comprehensive insight into the market access landscape. At Maverex, she collaborates with the value communications and evidence synthesis teams on diverse projects, including HTA submissions, global value dossiers, manuscripts, and targeted and systematic literature reviews. Her blend of clinical acumen and analytical expertise aid the development of robust, evidence-based solutions that address both patient and market needs.
Environmental Sustainability Assessments
Lindsay Nicholson, PhD
-
Lindsay leads our work in assessing the environmental impact of healthcare pathways and products. With over nine years in market access, she combines sustainability expertise with evidence generation and value communication. Lindsay specialises in developing high-quality, evidence-based materials, including global value dossiers, and value propositions to support product value demonstration. Skilled in literature reviews and HTA landscaping, she has experience of successful NICE and SMC submissions, HTA early engagement, and MHRA ILAPs. With a strong publication record in both market access and sustainability, she has also developed innovative communication tools, including podcasts and patient group materials, to support broad stakeholder engagement.
Environmental Analyses
Emily Archer Goode, PhD
Amy Swanston, PhD
Environmental Analyses
-
Amy brings broad experience in literature reviews, data analysis, and scientific communication across diverse disease areas, with a goal to turn complex data into simple, easily digested outputs. She has worked on environmental impact assessments, HTA briefing books, and large-scale data studies, with multiple publications and international conference presentations. Prior to joining Maverex, she worked in academia and the biotechnology industry on projects with applications in public health and defence.
Gregor Skeldon, PhD
-
For over 6 years, Gregor has been a Project and Product Manager specialising in market access, digital tool development, and environmental analyses initiatives. Their background in academia provides a strong foundation in scientific rigor, together with consultancy experience managing and delivering complex projects.
Gregor’s responsibilities include defining product strategy, leading cross-functional teams, and ensuring the timely delivery of high-quality deliverables, from value documents to software tools. By bridging deep domain expertise with disciplined project management, they ensure all initiatives, including software development, meet strategic goals and effectively communicate product value to diverse stakeholders.
Environmental Analyses
-
Emily is a Senior Analyst within the environmental and value communications team at Maverex. Her career in market access follows extensive academic and industry research experience, culminating in a PhD in Cancer Research. She applies her in-depth understanding of the scientific and medical industry in her role at Maverex. Emily is experienced in creating value communication materials, including global value dossiers, value demonstration plans, literature reviews and conference abstracts. As exemplified by her extensive publication record, she is highly adept in generating and submitting manuscripts to peer-reviewed journals.
Environmental Analyses
Evidence Synthesis
Zoe Marjenberg, PhD
-
Zoe leads the evidence synthesis team at Maverex. She is a seasoned literature review specialist with deep experience leading systematic and pragmatic reviews across clinical efficacy, quality of life, health economics, and epidemiology. Zoe has supported everything from epidemiological modelling to strategic drug development and horizon scanning. Skilled in meta-analyses (pairwise and network), Zoe also has a strong track record in manuscript writing and conference presentations. She brings expert knowledge of UK/EU HTA processes—especially for orphan drugs—and knows how to deliver evidence that drives decisions.
Evidence Synthesis
Masoumeh Kisomi, PhD
-
Masoumeh has over 10 years of experience conducting systematic, pragmatic, and targeted literature reviews across diverse therapeutic areas, including quality-of-life and cost-effectiveness studies. Her clinical foundation as a midwife, combined with an MSc and PhD in Public Health, provides a strong grounding in epidemiology, clinical research, and the broader market access landscape. Currently working in the evidence synthesis team, Masoumeh supports HTA submissions, methodological development, and research publications. She is skilled in study design, quality appraisal, and data interpretation, with extensive experience in academic writing and dissemination through conferences and peer-reviewed journals.
Evidence Synthesis
Kate Misso, MSc
-
With over 25 years of experience as an expert systematic searcher, Kate has worked extensively on systematic reviews, health technology assessments (HTAs), and economic evaluations within the pharmaceutical and biomedical research sectors. She has worked in academia (CRD), consultancy and held a dual role as a member of the InterTASC Evidence Review Group for NICE. She contributed to the NICE TAR programme, assessing submissions within the STA process and working on diagnostic assessment reviews (DAR). Kate’s research interests focus on improving transparency and compliance in reporting, and enhancing methodological quality. Kate is a member of Cochrane Information Retrieval Methods Group.
Evidence Synthesis
Daniel Mitchell, PhD
-
Daniel is a highly experienced scientist with 10+ years' experience in drug discovery and biotechnology, having publishing widely and working with academia and industry in previous roles.
Currently working in the evidence synthesis team, he brings experience in scientific writing, systematic, pragmatic and targeted literature reviews and several computer programming languages.
Evidence Synthesis
Rhiannon Green, MRes
Evidence Synthesis
-
Rhiannon is highly experienced in systematic, targeted, and scoping literature reviews across clinical, economic, environmental and quality of life areas. She brings expertise in data extraction, meta-analysis, and evidence synthesis, alongside a strong academic background in epidemiology and biomedicine. At the NIHR Innovation Observatory, she developed skills in horizon scanning and pipeline analysis. Rhiannon has a solid understanding of UK/EU HTA processes and is well-versed in academic writing, with research shared at leading conferences and published in peer-reviewed journals.
Nicola Nowak, MSci
-
Nicola has a strong academic background in biomedical sciences with a focus on neuroscience. She spent two years in the pharmaceutical industry, running quality-control analytical tests to pharmacopoeia standards, trend analyses, and second-person reviews.
Nicola currently works as part of the evidence synthesis team and is experienced in conducting systematic/landscape/targeted literature reviews, meta-analyses, as well as supporting HTA submissions. She is skilled in database searching, critical appraisal, and translating clinical and real-world evidence to inform healthcare decisions and strategy. Nicola is confident using SPSS and GraphPad, with some R experience.
Evidence Synthesis
Health Economic Modelling
Nina Embleton, PhD
-
Nina is a Senior Principal Consultant and Health Economic Modeller with over seven years of experience in market access consultancy and four years in modelling roles across other industries. She specialises in developing HTA-standard models in Excel and R, alongside advanced statistical analyses, including meta-analyses, survival modelling, and real-world evidence evaluation. Nina is experienced in assessing the environmental impact of healthcare products and patient care pathways and has overseen the development of innovative digital tools and application-based field models. She leads the Modelling and Statistics team, providing technical leadership, mentorship, and strategic project oversight across a range of therapeutic areas.
Health Economic Modelling
Luke Hubbert, MMath
-
Luke has extensive experience in large-scale environmental sustainability assessments, including global modelling of product and service impacts across patient pathways. He adapts life cycle analyses for different countries, pinpointing key differences and trends. A skilled coder (R, JavaScript), he’s built innovative digital tools for data analysis and visualisation—leading design and prototype development for unique environmental models. Luke designs economic evaluations in Excel and R across diverse disease areas and leverages this knowledge, along with industry-standard checklists, to rigorously validate models. Backed by a solid foundation in maths and statistics, he brings sharp modelling and data science capabilities to every project.
Health Economic Modelling
Henry Swales, MMathStat
-
Backed by a strong statistical background, Henry is a dedicated health economist skilled in developing health economic models from the ground up for varied purposes. From early-stage decision support to health technology submissions, Henry builds models tailored to meet specific decision-making needs. His expertise extends to planning and executing in-depth statistical analyses, ensuring that complex data yields meaningful insights. Henry’s work supports data-driven, evidence-based strategies, providing clients with the analytic foundation needed to make informed decisions across the healthcare landscape.
Health Economic Modelling
Cheryl Jones, PhD
-
Cheryl brings over 10 years of health economics experience across academia and consultancy. She has experience with building and adapting health economic models. Cheryl also has experience in RWE having set-up primary data collection studies, using surveys and chart reviews, and leading the statistical analysis. Her most recent experience involved project management of software projects which utilised GenAI to automate health economics tasks, such as the automatic updating of country-specific modelling reports. Cheryl is now focussing on understanding and quantifying the environmental impact of healthcare pathways, combining her technical expertise and knowledge of the healthcare industry.
Health Economic Modelling
Hosein Shabaninejad, PhD
Health Economic Modelling
-
Hosein is a Principal Consultant Specialist and Health Economist at Maverex, leading the modelling and statistical team. He has extensive experience in Health Technology Assessment (HTA), market access, and economic evaluations across a wide range of therapeutic areas. Before joining Maverex, Hosein worked as part of a NICE External Review Group (ERG) within an NIHR-funded programme, contributing to the appraisal of healthcare technologies and the development of economic models for NICE submissions. His expertise spans economic modelling, evidence synthesis, real-world data analysis, and global value dossier development. With a strong background in both academic research and industry practice, he provides strategic and technical leadership to deliver robust, evidence-based insights that support market access and policy decision-making.
John Bridgewood, MMathStat
Health Economic Modelling
-
John is a mathematician with a statistical background in survival analysis and modelling. His current role focuses on developing, adapting and validating health economic evaluations (cost-effectiveness, cost-utility, budget impact, early justifiable pricing models) as well as conducting statistical analyses across a plethora of different disease areas. HEOR modelling capabilities range from early-stage pricing and evidence gap identification-based evaluations through to the HTA submission level, predominantly utilising Microsoft Excel and R, with JavaScript coding capabilities too. He is also experienced in developing large-scale environmental sustainability assessments through life cycle analyses across countries globally to identify key trends and dissimilarities.
Medha Shrivastava, MSc
-
Medha has over four years of experience in healthcare economics, with a strong background in economics, econometrics, and statistics. She specialises in early-stage economic modelling and cost-effectiveness analyses for HTA submissions. She is an expert statistician with extensive experience performing survival analyses using both parametric and non-parametric methods for HTA submissions and has led methodological approaches for indirect treatment comparisons and meta-analyses. Medha has also analysed large real-world datasets to assess disease burden and supported life cycle analysis projects evaluating environmental impacts of patient care. In addition, she develops digital tools using R and JavaScript and is proficient in R, SQL, Stata, and Excel VBA.
Health Economic Modelling
Real-World Evidence
Anne Wilson, PhD
-
Anne brings over 15 years of experience in clinical epidemiology across consulting, pharmaceutical, and academic settings, with expertise spanning a wide range of therapeutic areas.
As Head of the Real World Evidence (RWE) Team at Maverex, she partners with clients to develop integrated evidence plans and generate high-quality, impactful RWE to inform product strategy and maximise product value.
Anne has extensive experience in the design, execution, and analysis of Phase III/IV clinical trials, as well as complex non-interventional studies. She also possesses a strong understanding of global regulatory and market access environments, along with the broader drug development landscape.
Real-World Evidence
Steady Chasimpha, PhD
-
With a strong background, and over five years of experience in epidemiology and statistics, Steady specialises in analysing real-world data (RWD) to address critical research questions related to disease burden, clinical effectiveness, healthcare resource use, and costs. He supports clients with identification of relevant RWD sources, development of real-world evidence (RWE) study protocols and study registrations. With extensive experience working with the Clinical Practice Research Datalink (CPRD) and proprietary datasets such as US Claims, Steady has advanced expertise in epidemiological research and healthcare analytics. He also works collaboratively with clients in disseminating research findings through preparation of conference abstracts and manuscripts for publication.
Real-World Evidence
Operations and Human Resources
Shannon Hurst
-
Shannon has over eight years of experience in HR and administration roles across engineering, digital, and health-related industries. She specialises in employee relations, people metrics, and aligning HR strategies with wider business goals. With a strong track record of helping organisations build engaged, high-performing teams, Shannon combines effective communication with data-driven decision-making. She’s passionate about applying best practice HR approaches to support positive workplace culture and performance. Committed to fostering inclusive, supportive environments, Shannon focuses on creating spaces where both individuals and businesses can grow and thrive.
Operations and Human Resources
Grant Richardson, BSc
-
As Business Operations Manager at Maverex, Grant leads the coordination of company processes, business accreditations, and operational strategy to keep the business running smoothly and efficiently. Grant has a strong background in biomedical science, with a focus on melanoma and immunology, and has contributed to published research in both areas. Prior to joining Maverex Grant worked at a diagnostic start-up, where he managed an ISO:13485 accredited laboratory and played a key role in business operations, quality management, R&D, and driving continual improvement. At Maverex, Grant applies this diverse experience to enhance efficiency, support innovation, and align business operations with the company’s mission.
Operations and Human Resources